CA2760166C - Derives d'isoxazole-pyridine - Google Patents
Derives d'isoxazole-pyridine Download PDFInfo
- Publication number
- CA2760166C CA2760166C CA2760166A CA2760166A CA2760166C CA 2760166 C CA2760166 C CA 2760166C CA 2760166 A CA2760166 A CA 2760166A CA 2760166 A CA2760166 A CA 2760166A CA 2760166 C CA2760166 C CA 2760166C
- Authority
- CA
- Canada
- Prior art keywords
- lower alkyl
- pyridine
- disorder
- carboxylic acid
- isoxazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159457 | 2009-05-05 | ||
| EP09159457.2 | 2009-05-05 | ||
| PCT/EP2010/055695 WO2010127976A1 (fr) | 2009-05-05 | 2010-04-28 | Dérivés d'isoxazole-pyridine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2760166A1 CA2760166A1 (fr) | 2010-11-11 |
| CA2760166C true CA2760166C (fr) | 2017-07-18 |
Family
ID=42371365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2760166A Expired - Fee Related CA2760166C (fr) | 2009-05-05 | 2010-04-28 | Derives d'isoxazole-pyridine |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8415379B2 (fr) |
| EP (1) | EP2427456B1 (fr) |
| JP (1) | JP5466292B2 (fr) |
| KR (1) | KR101367012B1 (fr) |
| CN (1) | CN102414206B (fr) |
| AU (1) | AU2010244553A1 (fr) |
| BR (1) | BRPI1013844A2 (fr) |
| CA (1) | CA2760166C (fr) |
| IL (1) | IL216007A0 (fr) |
| MX (1) | MX2011011489A (fr) |
| SG (1) | SG175867A1 (fr) |
| WO (1) | WO2010127976A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ608592A (en) | 2010-11-05 | 2015-08-28 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| EP2457569A1 (fr) * | 2010-11-05 | 2012-05-30 | F. Hoffmann-La Roche AG | Utilisation de composés pharmaceutiques actifs pour le traitement de conditions du système nerveux central |
| AU2012275435B2 (en) * | 2011-06-27 | 2016-07-21 | Boehringer Ingelheim Animal Health USA Inc. | Amido-pyridyl ether compounds and compositions and their use against parasites |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| WO2014001280A1 (fr) | 2012-06-26 | 2014-01-03 | Aniona Aps | Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa |
| CN104411699B (zh) | 2012-06-26 | 2017-06-13 | 萨尼奥纳有限责任公司 | 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途 |
| WO2014001279A1 (fr) | 2012-06-26 | 2014-01-03 | Aniona Aps | Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa |
| IN2014DN11027A (fr) | 2012-06-26 | 2015-09-25 | Aniona Aps | |
| WO2014001278A1 (fr) | 2012-06-26 | 2014-01-03 | Aniona Aps | Dérivé de phényle triazole et son utilisation pour moduler le complexe du récepteur gabaa |
| WO2015004534A2 (fr) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine |
| PT3010503T (pt) | 2013-06-21 | 2020-06-16 | Zenith Epigenetics Corp | Novos inibidores bicíclicos de bromodomínios |
| US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
| WO2016087942A1 (fr) * | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Pyridines substituées comme inhibiteurs de bromodomaine |
| WO2016087936A1 (fr) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Pyridinones substituées utilisées comme inhibiteurs de bromodomaines |
| US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| JP6721723B2 (ja) * | 2016-06-27 | 2020-07-15 | モグ リサーチ センター リミテッドＭｏｇｈｕ Ｒｅｓｅａｒｃｈ Ｃｅｎｔｅｒ Ｌｔｄ． | イソキサゾリン環を含むピリジン系化合物及び除草剤としての該用途 |
| MX2019006696A (es) | 2016-12-08 | 2019-08-21 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5. |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| KR20240005848A (ko) | 2021-05-05 | 2024-01-12 | 유니버시티 칼리지 카디프 컨설턴츠 리미티드 | 인지 장애의 치료에 유용한 헤테로아릴 화합물 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3525205A1 (de) * | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
| GB9808663D0 (en) | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic agents |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| IT1314191B1 (it) | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
| DE60001983T2 (de) | 1999-11-12 | 2004-01-29 | Neurogen Corp | Bicyclische und tricyclische heteroaromatische verbindungen |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| MXPA03011886A (es) | 2001-07-05 | 2005-03-07 | Lundbeck & Co As H | Piperidinias anilinicas sustituidas como antagonistas selectivos de mch. |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| US7071208B2 (en) | 2001-11-20 | 2006-07-04 | Eli Lilly And Company | β3 Adrenergic agonists |
| GB0128160D0 (en) * | 2001-11-23 | 2002-01-16 | Merck Sharp & Dohme | Novel compounds |
| AU2003290700A1 (en) | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| DE602005007350D1 (de) | 2004-06-01 | 2008-07-17 | Hoffmann La Roche | Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors |
| WO2005123672A2 (fr) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Inhibiteurs de kinase |
| PL1802566T3 (pl) | 2004-10-01 | 2009-05-29 | Hoffmann La Roche | Podstawione heksafluoroizopropanolem pochodne eteru |
| EP1812427A4 (fr) | 2004-10-15 | 2009-10-14 | Scripps Research Inst | Inhibiteurs oxadiazole cetone d'hydrolase d'amide d'acide gras |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2007009275A1 (fr) | 2005-07-20 | 2007-01-25 | Prospective Concepts Ag | Structures de coussin pneumatiques |
| ES2314943T3 (es) | 2005-09-19 | 2009-03-16 | F. Hoffmann-La Roche Ag | Derivados de isoxazolo como agonistas inversos de gaba a alfa. |
| US7334639B2 (en) * | 2005-09-30 | 2008-02-26 | M-I Llc | In-situ solidification of invert emulsion fluids to form gas tight annular barrier |
| WO2007052843A1 (fr) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | Compose amide heterocyclique et son utilisation |
| ES2374165T3 (es) | 2005-12-19 | 2012-02-14 | Glaxosmithkline Llc | Agonistas del receptor x farnesoide. |
| ES2452031T3 (es) | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compuestos y procedimientos para modular receptores FX |
| JP2007230909A (ja) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
| CA2651857A1 (fr) * | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Derives d'aryl-4-ethynyl-isoxazole |
| EP1894924A1 (fr) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Composés hétérocycliques de liason du FXR |
| EP1894928A1 (fr) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Composes heterocycliques de liaison au fxr |
| US7618973B2 (en) * | 2007-12-04 | 2009-11-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2009071476A1 (fr) * | 2007-12-04 | 2009-06-11 | F. Hoffmann-La Roche Ag | Dérivés isoxazolo-pyridine |
-
2010
- 2010-04-28 JP JP2012508992A patent/JP5466292B2/ja active Active
- 2010-04-28 US US12/768,762 patent/US8415379B2/en active Active
- 2010-04-28 SG SG2011080843A patent/SG175867A1/en unknown
- 2010-04-28 WO PCT/EP2010/055695 patent/WO2010127976A1/fr active Application Filing
- 2010-04-28 BR BRPI1013844A patent/BRPI1013844A2/pt not_active IP Right Cessation
- 2010-04-28 CN CN201080019819.2A patent/CN102414206B/zh active Active
- 2010-04-28 AU AU2010244553A patent/AU2010244553A1/en not_active Abandoned
- 2010-04-28 KR KR1020117028901A patent/KR101367012B1/ko not_active IP Right Cessation
- 2010-04-28 CA CA2760166A patent/CA2760166C/fr not_active Expired - Fee Related
- 2010-04-28 EP EP10715271.2A patent/EP2427456B1/fr active Active
- 2010-04-28 MX MX2011011489A patent/MX2011011489A/es active IP Right Grant
-
2011
- 2011-10-27 IL IL216007A patent/IL216007A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011011489A (es) | 2011-11-18 |
| JP5466292B2 (ja) | 2014-04-09 |
| IL216007A0 (en) | 2012-01-31 |
| CA2760166A1 (fr) | 2010-11-11 |
| AU2010244553A1 (en) | 2011-12-01 |
| CN102414206A (zh) | 2012-04-11 |
| KR20120018349A (ko) | 2012-03-02 |
| US8415379B2 (en) | 2013-04-09 |
| JP2012526071A (ja) | 2012-10-25 |
| BRPI1013844A2 (pt) | 2016-04-12 |
| KR101367012B1 (ko) | 2014-03-14 |
| US20100286132A1 (en) | 2010-11-11 |
| WO2010127976A1 (fr) | 2010-11-11 |
| CN102414206B (zh) | 2014-11-05 |
| SG175867A1 (en) | 2011-12-29 |
| EP2427456A1 (fr) | 2012-03-14 |
| EP2427456B1 (fr) | 2020-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2760166C (fr) | Derives d'isoxazole-pyridine | |
| EP2427458B1 (fr) | Dérivés d'isoxazole-pyridazine | |
| CA2760746C (fr) | Derives d'isoxazole-pyrazole | |
| CA2706990C (fr) | Derives d'isoxazolo-pyrazine | |
| US8173652B2 (en) | Isoxazole-isoxazoles and isoxazole-isothiazoles | |
| CA2759598C (fr) | Derives d'isoxazole-thiazole comme agonistes inverses du recepteur gaba a, utiles dans le traitement de troubles cognitifs | |
| JP2012526072A (ja) | Ｇａｂａ修飾薬としてのイソオキサゾール−ピリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150423 |
|
| MKLA | Lapsed |
Effective date: 20190429 |